Patents Assigned to Integrated DNA Technologies, Inc.
  • Patent number: 11965185
    Abstract: Described herein are CAS12A mutants from Lachnospiraceae bacterium and methods for use thereof. These mutants have enhanced DNA cleavage activities at non-canonical TTTT protospacer adjacent motifs (PAM) compared to the wild-type enzyme.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 23, 2024
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Liyang Zhang, Christopher Anthony Vakulskas
  • Patent number: 11926866
    Abstract: Methods for detecting on-target and predicted off-target genome editing events by providing a multiplex PCR reaction mixture with an on-target oligonucleotide primer and one or more off-target oligonucleotide primers and then hybridizing the on-target oligonucleotide primer and the one or more off-target oligonucleotide primers to target nucleic acid sequences, followed by cleaving blocking groups from the primers and extending the primers.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: March 12, 2024
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Joseph Dobosy, Caifu Chen, Mark Aaron Behlke, Garrett Richard Rettig
  • Patent number: 11913014
    Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: February 27, 2024
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
  • Patent number: 11788947
    Abstract: Systems and methods for controlling volumes of droplets is provided herein. In some cases, the systems comprise: a plurality of first light sources, a second light source, wherein a first light beam emitted a first light source of said plurality of first light sources is configured to intersect with a second light beam emitted from said second light source at an intersection area, wherein said system is configured to measure a characteristic of said droplet as it passes through said intersection area. Systems and methods for measuring volumes of droplets and for distinguishing between bubbles and droplets are also provided.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 17, 2023
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Keith Miller Anderson, Guillermo Alfredo Cornejo
  • Publication number: 20230257805
    Abstract: The present disclosure provides methods and kits for ligation-coupled PCR. Methods for performing ligation and PCR and, optionally, enzymatic digestion in a single closed tube are provided. Methods and kits for splint-mediated primer assembly and ligation-coupled PCR are also provided.
    Type: Application
    Filed: November 14, 2022
    Publication date: August 17, 2023
    Applicant: Integrated DNA Technologies, Inc.
    Inventors: Vladimir Makarov, Jordan Rosefigura, Bita Lahann, Robert D. Stedtfeld
  • Patent number: 11724261
    Abstract: A synthesizer system includes a vacuum block, a sealing plate coupled to the vacuum block, a synthesis plate having a plurality of wells, and an inflatable seal coupled to both the sealing plate and the synthesis plate and forming a seal between the sealing plate and the synthesis plate.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: August 15, 2023
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Robert West, Gregory Hodges, Justin Kline, Scott Steburg
  • Patent number: 11697836
    Abstract: A bottleneck in the Next Generation Sequencing (NGS) workflow is the quantification of libraries for accurate pooling and loading of the sequencing instrument flow cell or chip. Disclosed herein are methods that improve performance and reduce time compared to existing methods.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: July 11, 2023
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Vladimir Makarov, Sergey Chupreta
  • Patent number: 11692219
    Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: July 4, 2023
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Zachary Zwirko, Yu Zheng, Mirna Jarosz, Caifu Chen, Joseph Walder
  • Patent number: 11566282
    Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: January 31, 2023
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, John Robert Havens, Mirna Jarosz, Zachary Zwirko, Doron Lipson, Frank Soo Juhn
  • Patent number: 11566283
    Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: January 31, 2023
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mark Aaron Behlke, John Robert Havens
  • Patent number: 11459559
    Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 4, 2022
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
  • Patent number: 11447758
    Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 20, 2022
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
  • Patent number: 11427818
    Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: August 30, 2022
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
  • Patent number: 11308055
    Abstract: Disclosed herein are nucleic acid-based data storage systems and nucleic acid data storage constructs comprising reusable nucleic acid sequences, each representing information carried by a single bit (and, in some embodiments, one or more adjacent bits) within a bit string, and each furthermore representing the position of the single bit within the bit string. Also described are methods for storing data in the nucleic acid-based data storage systems and nucleic acid data storage constructs of the disclosure.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: April 19, 2022
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Joseph Alan Walder, Jeffrey A. Manthey, William E. Martin, III, Shawn Allen
  • Patent number: 11293022
    Abstract: This invention pertains to single-stranded carrier nucleic acids and their methods of use for enhancing genome editing ribonucleoprotein complex transfection into cells and the resulting enhancement of CRISPR editing on the target DNA within those cells, as well as introduction of chemical modifications which reduce the integration of the single-stranded carrier nucleic acids at double-stranded breaks.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: April 5, 2022
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Rolf Turk, Mark A. Behlke, Chris Vinci
  • Patent number: 11242542
    Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: February 8, 2022
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
  • Patent number: 11136567
    Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 5, 2021
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
  • Patent number: 11053537
    Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 6, 2021
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Mirna Jarosz, Madelyn Light, Jiashi Wang, Kristina Giorda
  • Patent number: 11034989
    Abstract: The invention provides methods for the synthesis of long oligonucleotides, genes and gene fragments. The methods include the manufacture of genes or gene fragments that can be then inserted into a variety of vectors.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: June 15, 2021
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Shawn Allen, Stephen Gunstream, Scott Rose
  • Patent number: 10982247
    Abstract: This invention relates to mutant DNA polymerases having an enhanced template discrimination activity compared with the corresponding unmodified DNA polymerase counterparts, wherein the amino acid sequence of the mutant DNA polymerase includes at least one substitution at residue positions structurally and functionally homologous or orthologous positions 783 or 784 of an unmodified Taq DNA polymerase.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 20, 2021
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, Joseph A. Walder, Richard Owczarzy, Scott D. Rose, Joseph R. Dobosy, Susan M. Rupp